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Abstract
The human APOBEC3G (A3G) DNA cytosine deaminase restricts and hypermutates DNA-based 
parasites including HIV-1. The viral infectivity factor (Vif) prevents restriction by triggering A3G 
degradation. While the structure of the A3G catalytic domain is known, the structure of the N-
terminal Vif-binding domain has proven more elusive. Here, evolution- and structure-guided 
mutagenesis was used to solubilize the Vif-binding domain of A3G permitting structural 
determination by NMR spectroscopy. A smaller zinc-coordinating pocket and altered helical 
packing distinguish it from catalytic domain structures, and help explain the reported inactivity of 
this domain. This soluble A3G N-terminal domain is bound by Vif, which enabled mutagenesis 
and biochemical experiments to identify a unique Vif-interacting surface formed by α1-β1, β2-α2, 
and β4-α4 loops. This structure sheds new light on the Vif-A3G interaction and provides critical 
information for future drug development.
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
*Correspondence to H.M. (matsu029@umn.edu).
4Present addresses: Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, 
USA (M.S), Department of Physical Medicine and Rehabilitation, University of Minnesota, Minneapolis, Minnesota, USA (J.Z), 
Program in Computational Biology and Bioinformatics, Yale University, New Haven, Connecticut, USA (L.C), Department of 
Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan (M.H).
ACCESSION CODES
Atomic coordinates: Protein Data Bank (PDB) code 2MZZ
NMR constraints: Biological Magnetic Resonance Bank (BMRB) number 25509
AUTHOR CONTRIBUTIONS
T.K. designed the strategy for searching soluble A3G NTD mutants and all of A3G NTD mutants, performed harvest assay, Vif-
binding assay in E. coli, Vif-dependent degradation assay, and deamination assay, prepared NMR samples, determined the solution 
structure; E.M.L. performed single-cycle infectivity assays; M.S. optimized human cell experiments; S.S. analyzed surface charge 
distribution and binding pocket volumes of the NTD structure; J.Z. supported harvest assays; L.C. and M.H. supported preparation of 
expression plasmids and the Vif-binding assay in E. coli. T.K., E.M.L., S.S., C.A.S., R.S.H. and H. M. contributed to writing and 
editing the manuscript.
HHS Public Access
Author manuscript
Nat Struct Mol Biol. Author manuscript; available in PMC 2015 December 01.
Published in final edited form as:
Nat Struct Mol Biol. 2015 June ; 22(6): 485–491. doi:10.1038/nsmb.3033.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
INTRODUCTION
APOBEC3 proteins are single-stranded DNA cytosine deaminases that are part of a larger 
network of innate immune effector proteins that serve to limit the replication of many 
diverse parasitic elements including the AIDS virus HIV-11–3. Up to seven family members, 
APOBEC3A, B, C, D, F, G, and H, can be expressed in a single human cell4. A combination 
of overexpression, knockdown, knockout, and separation-of-function studies have shown 
that A3D, A3F, A3G, and A3H contribute to HIV-1 restriction and hypermutation in CD4+ 
T lymphocytes (recent publications5–7 and references therein). A3D, A3F, and A3H catalyze 
C-to-U deamination in 5′-TC dinucleotide motifs, whereas A3G catalyzes deamination in 5′-
CC motifs. These viral cDNA deamination events lead to G-to-A mutations in hallmark GA 
and GG dinucleotide motifs respectively. A3G has two structural domains, an N-terminal 
pseudo-catalytic (NTD) and C-terminal catalytic (CTD) domain8,9. The CTD alone dictates 
the observed local dinucleotide preference10,11,12. The NTD is catalytically inert but still 
strongly binds RNA and single-stranded DNA and forms a ribonucleoprotein complex with 
the viral Gag protein, enabling encapsidation [e.g. 13–17].
HIV-1 encodes Vif as a counter-defense mechanism against A3 mediated restriction18,19. 
Vif interacts with core binding factor β (CBF-β), CUL5, ELOB, ELOC, and RBX2 proteins 
to form an E3 ubiquitin ligase complex20,21. As a consequence, A3G and other potentially 
restrictive A3 enzymes are polyubiquitinated and degraded by proteasome before being 
encapsidated [e.g. 18,19,22–25]. The interaction between Vif and A3G has been studied 
extensively, and key regions for the interaction have been identified, which include 126-
FWDPDYQ-132 of A3G and 22-KSLVK-26, 40-YRHHY-44, 69-YWGL-72 of Vif26–29. 
However, insolubility has limited structural information of the A3G-Vif complex.
A crystal structure of the Vif-CBF-β-ELOBC-CUL5 complex was reported recently30. Vif 
has two structural domains called alpha/beta and alpha. A3G-binding residues, including 
K22, K26, 40-YRHHY-44 and W70, are located in the alpha/beta domain30. Although the 
structure of catalytically active A3 proteins A3A and A3C, as well as the catalytic domains 
A3G CTD and A3F CTD, were solved by NMR and X-ray crystallography12,31–38, a 
structure of the N-terminal pseudo-catalytic, Vif-binding domain of A3G has thus far proven 
elusive. To address this major gap in knowledge, we have generated a soluble A3G NTD 
variant (sNTD) that binds the Vif-CBF-β-ElOBC complex. The sNTD has 80% amino acid 
sequence identity to wildtype A3G NTD. In this paper, we report the three-dimensional 
structure of sNTD and mutationally interrogate the Vif-binding regions.
RESULTS
Engineering a soluble A3G Vif-binding domain
The wildtype A3G NTD was insoluble in E. coli. To overcome this technical hurdle, we 
compared the amino acid sequence of A3G NTD with A3A, A3B CTD, and A3G CTD, 
which were soluble and amenable to structural studies12,31–34,37. A3A, A3B CTD, and A3G 
CTD were catalytically active, but did not interact with Vif, and belong to the same 
phylogenetic subgroup, i.e., the Z1 group39 (Fig. 1a). An alignment of A3A, A3B CTD, and 
A3G CTD allowed us to generate a consensus Z1 amino acid sequence (Supplementary Fig. 
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1a). We expressed and purified the consensus Z1 protein from E. coli, and found that it was 
soluble and folded. Wildtype A3G NTD amino acid residues were used to replace consensus 
Z1 residues one at a time, and all of the resulting constructs were tested for protein 
expression, solubility, and stability. We used NMR to evaluate soluble derivatives for signal 
dispersion and homogeneity. Ultimately, 80% amino acid sequence identity to wildtype 
NTD was achieved without substantially compromising solubility or quality of NMR spectra 
(Fig. 1b, c). Additional wildtype A3G amino acids were not tolerated (Supplementary Fig. 
1b, c). We henceforth refer to this soluble A3G NTD construct as sNTD.
Solution structure of sNTD
We generated a series of 15N, 13C, and/or 2H isotope-labeled protein samples to determine 
the solution structure of sNTD using state-of-the-art NMR techniques combined with amino 
acid-specific labeling techniques (representative NMR spectra are shown in Supplementary 
Fig. 2)31,40. Each sample was subjected to size-exclusion chromatography for purification, 
and the monomeric status was evaluated by the elution profile. sNTD eluted with a major 
peak corresponding to a molecular weight of 17 kDa and a minor peak corresponding to 47 
kDa (Fig. 1b); the theoretical molecular weight of sNTD is 21 kDa. sNTD exhibited fair 
quality of NMR spectra with most amide proton signals resolved in a transverse relaxation-
optimized spectroscopy (TROSY)41 spectrum, although signal intensities were 
inhomogeneous, suggesting diverse dynamics throughout sNTD (Supplementary Fig. 3). 
Using conventional triple resonance NMR spectra40, we assigned backbone signals 
(1HN, 15N, 1Hα, 13Cα and 13C′) for 146 residues (81.1%) of sNTD. 24 residues were 
missing from TROSY spectra due to severe line broadening, suggesting conformational 
exchange. Nuclear Overhauser effect (NOE) signals and a 1H/2H-exchange experiment 
depicted sNTD to contain a β-sheet of five β-strands arranged in the order of β2_(54–56)-
β1_(36–42)-β3_(85–92)-β4_(113–120)-β5_(148–152) with β2-β1-β3 in an anti-parallel 
orientation, and β3-β4-β5 in a parallel orientation (Supplementary Fig. 4). 1H, 1H-NOE 
patterns indicated that β2-β1 form an antiparallel β-sheet, however, only Y37 NH from β1 
showed slow 2H exchange with solvent, whereas F54 NH and G56 NH from β2 exchanged 
completely with solvent within one hour (Supplementary Fig. 4 and data not shown). Thus, 
hydrogen bonds between F54 NH and V39 CO and G56 NH and Y37 CO were weaker than 
that between Y37 NH and G56 CO, indicating that the structure and motions of β 2 is likely 
to be less restrained compared to the other β strands.
The sNTD solution structure was determined with 1609 distance and 106 dihedral angle 
restraints (structural statistics summarized in Table 1). The structure of sNTD has six alpha-
helices, including α1_(16–19), α2_(68–75), α3_(98–108), α4_(131–140), α5_(154–164), 
and α6_(178–194), organized around the β-strands described above (Fig. 2). Secondary 
structures were well defined, although α1, β2 and α2 were less converged compared to other 
secondary structures (Fig. 2a). The poorer convergence for β2 was indicative of weaker 
hydrogen bonding with β1. The loop between β1 and β2 (β1-β2 loop) was disordered 
because of insufficient NOE restraints. Residues located in the β1-β2 loop (E38, V39, K40, 
K42, G43, S45, R46) and the α2-β3 loop (Q84, E85, Y86) each showed two weak signals in 
TROSY spectra (Supplementary Fig. 3). Since the β1-β2 and α2-β3 loops face each other in 
the sNTD structure, these two loops may exchange between two conformations (Fig. 2b).
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The overall structure of sNTD was similar to other A3 proteins, including A3A, A3C, A3F 
CTD, and A3G CTD12,31–38 (Fig. 3a). However, the sNTD structure also had several unique 
features. First, the start of α2 is residue 68 of sNTD, one residue after the conserved 
glutamic acid residue (E67), whereas in α2’s of catalytically active A3 domains the helix 
starts one residue prior to the conserved glutamic acid. This structural difference 
substantially affected the spatial positioning of E67, locating the residue too far from the 
Zn2+ ion to participate in catalysis (Fig. 3b). Second, the α2 N-terminus was tilted toward 
the C-terminus of α3, an orientation not seen in any reported A3 catalytic domain structures 
(Fig. 3c). These two features provided a likely explanation for prior studies that assigned 
catalytic activity exclusively to the C-terminal domain8,9,42. Third, sNTD lacked a bulge 
structure present in the β2 region of A3A and A3G CTD (Fig. 3d). The β2 strand of sNTD 
was shorter than in other A3s, and located in the position of β2′ of the β2-bulge-β2′ structure 
of A3A and A3G CTD (Fig. 3d)12,31,32,34,37.
We substituted 20% of wildtype residues to solubilize NTD. Two thirds of the substituted 
residues are located in loops, including Δ(M1-R11), Y13D, R14P, Y22N, L62D, Δ(R78), 
A109Q, D110P, P111T, K112H, F126A, K141A, R142G, Δ(D143-R146), R169G, E170A, 
L171P, E173Q, N176D and N177G, whereas the remaining substitution are in helices, 
including F71L, H72S, W73L and F74V in α2, T101A in α3, C139A in α4, P179D, K180E, 
Y181H, Y182S, I183Q, L184A, H186S, I187G and M189R in α6, with the exception of 
M149I in β2.
sNTD is catalytically inactive in vitro—Because our solublization strategy started with 
the consensus sequence of several active deaminases, we next asked if sNTD possessed 
catalytic activity using one-dimensional 1H NMR spectra11,12. As a positive control, 
catalytically active A3G CTD variant (CTD-2K3A)31 was incubated with substrate DNA 
(5′-ATTCCCAATT-3′)12, and a signal corresponding to the uridine H5 proton emerged 
within 30 minutes at 5.72 ppm (Supplementary Fig. 5d). This result indicated that 
CTD-2K3A had catalyzed the first deamination reaction (5′-CCC to 5′-CCU). Within 24 
hours, CTD-2K3A completed the second deamination reaction, 5′-CCU to 5′-CUU, resulting 
two H5 proton signals, one at 5.74ppm and the other at 5.81 ppm (Supplementary Fig. 5e). 
By contrast, sNTD did not cause changes to the NMR spectrum of the substrate DNA even 
after 24 hours (Supplementary Fig. 5f). Thus, sNTD lacks detectable deaminase activity, 
consistent with prior studies demonstrating the catalytic inactivity of this domain8,9,42.
sNTD binds Vif—We used GST-pull down experiments to monitor interaction between 
sNTD and Vif-CBF-β-ELOBC (VCBC) co-expressed in E. coli. sNTD bound to the VCBC 
complex (Fig. 4a, lane 10). H43A and Y44A substitutions in Vif reduced binding to 
undetectable levels (Fig. 4a, lane 11). Since F126 of wildtype NTD had been substituted to 
an alanine in sNTD in order to increase solubility, we reversed this mutation and tested 
binding to the VCBC complex. sNTD(F126) bound more strongly to the VCBC complex 
than the original sNTD construct (Fig. 4a, lane 8), and this interaction became undetectable 
when Vif(H43A Y44A) was used instead of wildtype Vif (Fig. 4a, lane 9). The location of 
A126 appeared to be in the middle of the loop between β4 and α4, where it was exposed to 
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solvent (Fig. 4b). This surface location was important because the A126F substitution was 
unlikely to alter either secondary or tertiary structural elements.
F126 is important for Vif-mediated degradation—We created a construct in which 
sNTD was fused to wildtype CTD (A3G sNTD-CTD) and tested whether this construct 
behaves similarly to wildtype full-length A3G in a Vif-mediated degradation assay (Fig. 4c). 
Wildtype A3G was used as a positive control and, as expected, demonstrated reduced 
protein levels in 293T cells when co-expressed with Vif (Fig. 4c, lane 3) compared to 
expression alone (Fig. 4c, lane 1). The A3G protein level was restored by addition of 
protease inhibitor MG132 (Fig. 4c lane 4). We used a double mutation of H43A and Y44A 
in Vif (Fig. 4c lane 5) and D128K in A3G (Fig. 4c lane 9) as negative controls because these 
mutations have been shown to impair Vif-mediated degradation of A3G18,26,43–47. 
Interestingly, A3G sNTD-CTD protein levels were not reduced when co-expressed with Vif 
(Fig. 4c lane 15). Because sNTD(F126) bound to the VCBC complex more strongly than 
sNTD in vitro (Fig. 4a lane 8), we prepared a construct with sNTD(F126) fused to wildtype 
CTD [sNTD(F126)-CTD] and tested its protein stability in a Vif-mediated degradation 
assay. sNTD(F126)-CTD exhibited reduced protein levels in the presence of Vif (Fig. 4c, 
lane 21), which were restored by co-expression with Vif(H43A Y44A) (Fig. 4c, lane 23) or 
when cells were treated with MG132 (Fig. 4c, lane 22). Furthermore, adding the Vif-
antagonizing single amino acid substitution, D128K, protected the sNTD(F126 D128K)-
CTD construct from being degraded by Vif (Fig. 4c, lane 27). Prior studies have implicated 
the importance of F126 in Vif-binding and Vif-mediated degradation of A3G26,28,48. Thus, 
these data indicate that a single amino acid reversion (F126) can restore Vif-susceptibility to 
the A3G sNTD-CTD construct, and that the overall mechanism of Vif-mediated degradation 
is preserved in this construct.
sNTD lacks antiviral activity—We compared wildtype A3G, sNTD-CTD, and 
sNTD(F126)-CTD constructs in HIV-1 restriction experiments (Fig. 4d). As reported in 
previously, wildtype A3G packaged into vif-deficient HIV-1 particles and restricts viral 
infectivity in a dose dependent manner (Fig. 4d, lanes 1–4). Antiviral activity was strongly 
counteracted by Vif as evidenced by less A3G in cells and viral particles, and mostly 
restored viral infectivity (Fig. 4d, lanes 5–8). In contrast, sNTD-CTD resisted Vif-mediated 
degradation and failed to package substantially into viral particles, despite near wildtype 
A3G levels of cellular expression (Fig. 4d, compare lanes 17–20 and 21–24). However, as 
described above in co-expression studies, a single amino acid substitution A126F 
[(sNTD(F126)-CTD], restored the susceptibility of this construct to Vif-mediated 
degradation but did not restore packaging and restriction activities (Fig. 4d, compare lanes 
9–12 and 13–16). These data confirmed that the sNTD(F126)-CTD construct is functional 
for Vif degradation but compromised for packaging and restriction. Because packaging 
requires the formation of a ribonucleoprotein complex with Gag [e.g. 13–17] and similar 
regions of A3G have been implicated in both the Vif interaction and RNA binding, the 
sNTD(F126) variant appeared to separate these two activities by preserving the capacity to 
be bound and degraded by Vif and losing the capacity to bind RNA (which also manifests as 
packaging and restriction deficiencies).
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Vif binding to sNTD differs from A3C and A3F—We used sNTD variants, E. coli co-
expression and GST co-purification as described above to identify amino acid residues 
required for interaction of sNTD with the VCBC complex. Substitution Y19 at the C-
terminus of α1, I26, L27 and W34 in the α1-β1 loop, V58 and Y59 of the β2-α2 loop, and 
Y124, W127 and D128 from the β4-α4 loop decreased binding to the VCBC complex by 
greater than 50% (Fig. 5a, representative SDS PAGE gel images are provided in 
Supplemental Fig. 5g). These residues substantially expanded the size of the A3G NTD 
surface area required for Vif interaction (Fig. 5b). Interestingly, using a different 
experimental approach, Lavens et al. implicated a similar surface area (Fig. 5c)49. Thus, the 
A3G NTD Vif-binding surfaces appeared to be in distinct areas from that of A3C and A3F 
CTD, which are formed by residues located in the α2 and α3 helices (Fig. 5d and 5e)38.
DISCUSSION
We used sequence conservation and restorative mutagenesis to engineer a soluble variant of 
A3G NTD, which is 80% identical to the wildtype enzyme (Fig 1a). This variant, like 
wildtype A3G NTD, is not catalytically active but still binds Vif and succumbs to Vif-
mediated degradation (Fig. 4 and Supplementary Fig. 5f). This engineering approach, while 
labor intensive, is applicable to other systems that have evaded structural characterization 
due to protein solubility issues.
We used NMR spectroscopy to solve the structure of sNTD, representing the first structure 
of an APOBEC3 non-catalytic domain and the first structure of the Vif-binding domain of 
A3G. Our results suggest a mechanistic basis for the lack of catalytic activity. Zn2+ is 
coordinated by residues H65, C97, and C100 at the protein interior (Fig. 3b) and contacts the 
hydrophobic side chains of L35, W90, I92, and M104 (Supplementary Fig. 6a). These 
interactions reduce accessibility for a putative target cytosine, as the pocket volume of the 
Zn2+ coordinating region is reduced compared to A3G CTD (Supplementary Fig. 6b). The 
active site pocket volume of A3G-CTD is about 400 Å3, while that of sNTD is 
approximately 100 Å3, which is smaller than the volume of a cytosine nucleobase. This 
result supports the general trend observed for catalytically active and inactive domains50. In 
addition, conserved glutamic acid E67 of sNTD is not in a position where Zn2+ coordination 
is possible, preventing E67 from performing a catalytic role (e. g.51, Fig. 3b and 
Supplementary Fig. 6a). This altered position can be attributed to changes at the N-terminus 
of α2 helix, where A3G NTD has a proline at residue 66 just prior to E67 that shortens this 
helix to begin at M68. In all catalytically active A3 domains the helix begins at A66.
To make soluble NTD we had to make four amino acid substitutions in α2, including F71L, 
H72S, W73L and F74V, although they are conserved mutations among APOBEC3 proteins 
(Supplementary Fig. 6c). Residues 71 and 74 interact with F70 (α2), W90 (β3) and F107 
(α3), and F70, W90, and F107 interact with Y37 (β1), V39 (β1), and V88 (β3). Together, 
these residues form a hydrophobic core that stabilizes the β1-α2-β3-α3 structure 
(Supplementary Fig. 6d). All known A3 protein structures have the similar hydrophobic core 
involving corresponding residues12,31–38. Residues 72 and 73 are not involved in the 
hydrophobic core of known A3 structures, and we have shown that these residues can be 
substituted with alanine without compromising catalytic activity of A3G CTD52. Thus, 
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substitutions at residues 71–74 are unlikely to be responsible for the unique structural 
features of α2 and α3 of sNTD.
The known variant of Vif(H43A Y44A)26 that disrupts wildtype A3G binding also does not 
permit binding to sNTD, suggesting that contacts made through H43 and Y44 are 
maintained between sNTD and Vif. However, sNTD fused to wildtype CTD was largely 
resistant to the Vif-mediated degradation. We found that A126 was responsible for this 
reduction, as replacement of this alanine with endogenous phenylalanine increased 
interaction with the VCBC complex, and restored susceptibility to Vif-mediated 
degradation. These results confirmed the importance of A3G F126 in Vif-binding, and, 
together with additional mutant data demonstrated that the sNTD construct is a good 
structural mimic of wildtype A3G NTD.
A caveat of sNTD function is that neither sNTD-CTD nor sNTD(F126)-CTD were able to 
incorporate into viral particles or restricted HIV-1 infection. Encapsidation requires 
interaction with RNA and Gag protein[e.g. 13,14,53–55]. The failure of sNTD variants to 
encapsidate is most likely due to an abrogated interaction with RNA, because no interaction 
between sNTD and RNA could be detected in a phosphate buffer containing 100 mM NaCl 
(data not shown). This loss may be due to deletion and/or substitution of basic residues, 
including K2, R6, R11, R14, R78, K113, K141, R142, R146, R169 and K180 in sNTD 
(Figure S1). Future studies may be able to use sNTD as a starting point to determine 
residues essential for encapsidation and RNA-binding.
The Vif-binding regions of sNTD identified by this study, including α1-β1 β2-α2 and β4-α4 
loops provide a structural epitope for Vif binding and validate previous studies with 
wildtype A3G26,49,56,57 (Fig. 5b, 5c). The β4-α4 loop contains residues 124-YYFWD-128 
that are known to be important for Vif-mediated A3G degradation26,58. Structures of the 
A3C and A3F Vif-binding domains have been solved, and their Vif-binding surfaces were 
mapped by mutagenesis, co-immunoprecipitation, and degradation assays to a different 
surface35,36,38,59. In these cases, Vif is proposed to bind a continuous surface located on α2 
and α3 helices of A3F CTD and A3C away from the catalytic zinc (Fig. 5d and 5e). 
Residues F74, L80, Y86, and F107 were found to be critical for the A3C binding to Vif but, 
consistent with our results, not important for Vif-mediated degradation of A3G38. Previous 
studies showed that a negatively charged region around D128 appears important for binding 
to Vif (Supplementary Fig. 6b), as substitution of this amino acid abrogates binding to 
Vif26–29. A3G-CTD has a more positively charged (blue) profile in the corresponding area 
that likely interferes with binding to Vif30 (Supplementary Fig. 6b). In summary, we report 
the first structure of the Vif-binding domain of A3G (sNTD), which further elaborates a 
novel mode of Vif-binding and provides a substrate for future structural studies of the entire 
A3G-Vif ligase complex, as well as drug discovery.
ONLINE METHODS
Plasmids, antibodies, and reagents
DNA fragments coding the A3 consensus protein (Supplementary Fig. 1a) or wildtype A3G 
NTD (residues 1–196) were synthesized with codons optimized for expression in E. coli 
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(Genscript). All DNA fragments coding A3G NTD variants were prepared with a PCR-
based method using the synthesized DNAs coding the consensus protein or wildtype A3G 
NTD as a template. The prepared DNA fragments were inserted into NdeI/XhoI site of 
pCold-GST vector61. DNA fragment coding soluble A3G CTD variant (A3G CTD-2K3A 
that contains residues 191–384 with mutations L234K C243A F310K C321A C356A) was 
obtained with a PCR-based method using the previously prepared expression vector31, and 
was inserted into Nde I/Xho I site of pCold-GST vector61. For expression of Vif (Vif-176, 
residue 1–176) and CBF-β (residue 1–141) in E. Coli, codon-optimized DNA fragments 
coding those proteins (Genscript) were inserted into BamHI/HindIII and NdeI/XhoI sites of 
pRSFDuet vector (Novagen), respectively. Vif-176(H43A Y44A) expression vector was 
prepared in the same manner with a PCR-based method using Vif-176. For expression of 
elongin B (residue 1–118) and elongin C (residue 17–112) in E. coli, DNA fragments coding 
those proteins were inserted into BamHI/HindIII and NdeI/XhoI sites of pACYCDuet vector 
(Novagen), respectively. DNA fragments coding Wildtype A3G NTD (residue 1–196), CTD 
(residue 197–384), or sNTD (residue 1–180) were synthesized with codons optimized for 
expression in human cells (Genscript). D128K substitution was introduced to the A3G NTD 
construct with a PCR-based method. Similarly, sNTD variants, including sNTD(D128K), 
sNTD(F126), and sNTD(F126 D128K), were prepared with a PCR-based method using the 
DNA fragment encoding sNTD as a template. Each DNA fragment encoding NTD and its 
variants was combined with the wildtype A3G CTD using a PCR-based method to yield a 
full-length construct including sNTD-CTD, sNTD(F126)-CTD and sNTD(F126 D128K)-
CTD. All full-length constructs were inserted into NheI/HindIII site of pcDNA3.1 myc-
His(-) A vector (Invitrogen). pcDNA-HVif expression plasmid was provided by Dr. Klaus 
Strebel at NIH. A double mutation H43A and Y44A were introduced to pcDNA-HVif with a 
PCR-based method to generate pcDNA-HVif(H43A Y44A). DNA sequences of all 
constructs were verified by DNA sequencing. DNA oligomers for PCR and deamination 
assay were purchased from Integrated DNA Technologies. Mouse monoclonal anti-c-myc 
antibody (9E10) was purchased from Sigma-Aldrich. Mouse monoclonal anti-Vif antibody 
(319) and mouse monoclonal anti-α-tubulin antibody (DM1A) were purchased from Abcam. 
Anti-mouse IgG antibody conjugated with a fluorescent dye was purchased from Rockland 
Immunochemicals (Code# 610-132-121). All stable-isotope labeled reagents, including 
[15N]-ammonium chloride, [13C]-D-glucose, [2H, 13C]-D-glucose, deuterium oxide, [15N]-
L-phenylalanine (Phe), [15N]-L-isoleucine (Ile), [15N]-L-lysine (Lys), [15N]-L-leucine 
(Leu), [15N]-L-arginine (Arg), [15N]-L-tyrosine (Tyr), [13C]-L-alanine (Ala), [13C]-Phe, 
[13C]-Ile, [13C]-Lys, [13C]-Leu, [13C]-L-methyonine (Met), [13C]-Arg, [13C]-L-threonine 
(Thr), [13C]-Tyr, [13C]-L-valine (Val), [2H, 13C, 15N]-algal amino acid mixture, [2H]-
choline o-sulfate, were purchased from Cambridge Isotope Laboratories.
Protein expression and purification
The consensus protein (Supplementary Fig. 1a), sNTD, and their variants were prepared in 
the similar manner described previously31. BL21 (DE3) cells (Invirogen) were transformed 
with a prepared pCold-GST expression vector61 based plasmid, and grown at 37°C in M9 
medium containing 100 μg ml−1 of ampicillin until reaching an optical density at 600 nm of 
0.6–0.8. After the addition of 0.2 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) and 10 
μM ZnCl2, the cells were further incubated at 16°C for overnight. The bacterial cells were 
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harvested by centrifugation and resuspended with a lysis buffer [50 mM sodium phosphate, 
pH7.3, 150 mM NaCl, 0.005% Tween-20, and 0.5 mM tris(2-Carboxyethyl)phosphine 
(TCEP)]. The lysed cells were disrupted by sonication and then centrifuged. The supernatant 
was applied to glutathione-immobilized resin (GE Healthcare life sciences) and the resin 
was washed with the lysis buffer. The proteins bound to the resin was digested by HRV 3C 
protease (GE Healthcare life sciences) for overnight. The digested proteins were applied to 
Superdex-75 column (GE Heathcare life sciences) equilibrated with a buffer (10 mM 
sodium phosphate, pH7.3, 100 mM NaCl, 0.005% Tween-20, 0.5 mM TCEP, and 0.01% 
NaN3). The fractions including the protein of interest were collected and the protein was 
concentrated to 100–200 μM by using Amicon Ultra (Millipore). For NMR experiments, 0.5 
M choline o-sulfate, 5% deuterium oxide, and 20 μM 2,2-dimethyl-2-silapentane-5-sulfonate 
sodium salt (DSS) were added to the protein solution. To prepare isotope-labeled proteins, 
M9 medium was prepared with 60% or 85% deuterium oxide with [15N]-ammonium 
chloride and [13C]- or [2H, 13C]-D-glucose. When the cells were grown in 85% deuterium 
oxide, 1g L−1 [2H, 13C, 15N]-algal amino acid mixture was added prior to the IPTG 
induction to enhance the protein harvest. To prepare amino acid selectively [13C]- or [15N]-
labeled proteins, an amino acid uniformly labeled with 13C or 15N was added to the medium 
containing 85% deuterium oxide prior to the IPTG induction. Similarly, to prepare amino 
acid selectively protonated proteins, an amino acid without any isotope labeling was added 
to the medium containing 85% deuterium oxide prior to the IPTG induction.
NMR spectroscopy
NMR spectra were measured using Bruker AV700, AV850, and AV900 spectrometers 
equipped with cryogenic probes at 298K (MNMR center at University of MN). Sequential 
assignments of the backbone 1H, 13C, and 15N resonances of sNTD were achieved by triple-
resonance NMR techniques combined with amino acid selective labeling41,62–65. 
Assignments of side chain 1H and 13C resonances were achieved by using a combination 
of 1H,13C-HSQC spectra of amino acid selectively [13C]-labeled sNTD (Supplementary Fig. 
2) and 1H,1H-NOESY66 spectra of amino acid selectively protonated sNTD. 1H chemical 
shifts were directly referenced to DSS, while 13C and 15N chemical shifts were indirectly 
referenced by the absolute frequency ratios (13C/1H) = 0.251449530 and (15N/1H) = 
0.101329118 with internal DSS67. All NMR spectra were processed and analyzed by using 
NMRPipe68 and Sparky69, respectively.
Structure calculations
The solution structures of sNTD were calculated with a distance geometry-simulated 
annealing protocol using X-PLOR-NIH70. The structure calculations and NOE peak 
assignments were performed in an iterative and manual manner. For distance restraints, the 
lower limitation was set to 1.8 Å and the upper limitation was set to 2.5, 3.0, 3.5, 4.0, 4.5, or 
5.0 Å according to the NOE cross-peak intensity. Additionally, pseudo-atom corrections 
were applied66. In total, 1543 distance restraints were collected from 13C- and 15N-edited 
NOESY spectra and a series of 1H, 1H-NOESY spectra using amino acid selectively 
protonated sNTD. A total of 106 backbone dihedral angles (ϕ) were estimated using TALOS 
software based on 13Cα, 13Cβ, and 13C′ chemical shifts71. A total of 33 hydrogen bonds 
were identified from an H/D-exchanging experiment and the structures calculated in the 
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early stage. The hydrogen bond restraints, 2.3–3.3 Å for N-O and 1.3–2.3 Å for HN-O, were 
introduced into the late stage of calculations. Additionally, Zn2+ ion and empirical restraints 
between Zn2+ ion and sNTD residues H65, C97, and C100 were introduced into the late 
stage of the calculations12. A total of 100 structures were calculated and the 10 lower-energy 
structures were selected. These 10 structures were used for the further calculation of an 
energy-minimized average structure. The quality of obtained structures was analyzed using 
MOLMOL72 and PROCHECK programs73. Structural figures were generated using 
MOLMOL and MacPyMOL softwares (Schrödinger).
Protein harvest assay
To monitor expression level and relative solubility of A3G NTD variants, the 
aforementioned protein expression and purification procedures were applied. The volumes 
of media (400 ml), lysis buffer (25 ml), and glutathion-immobilized resin (100 μl) were 
strictly fixed. The resin bound to the protein was resuspended with lysis buffer to adjust the 
total volume to 200 μl. 5 μl of the resuspension was applied to a sodium dodecyl sulfate 
(SDS) polyacrylamide gel electrophoresis (PAGE) that was stained with Coomassie brilliant 
blue, and quantified for measured protein band density by Image J provided by US National 
Institute of Health. Each variant was independently cultured three times to calculate mean 
and s. d.
DNA deamination assay
Synthesized DNA fragment d(5′-ATTCCCAATT-3′)12 was dissolved in a buffer (10 mM 
sodium phosphate, pH7.3, 100 mM NaCl, 0.005% Tween-20, and 0.5 mM TCEP) at a 
concentration of 100 μM. Purified A3G CTD-2K3A or sNTD was added to the DNA 
solution at a final concentration of 20 μM. The mixture was incubated at 25°C. One-
dimensional 1H spectra were measured 0.5, 3, and 24 hours after the addition of protein.
E. coli co-expression and GST-pull down assay
BL21 (DE3) cells were transformed with a pCold-GST-NTD variant expression plasmid, 
pRSFDuet-Vif-176-CBF-β, and pACYCDuet-EloBC and grown at 37°C in 400 ml of Luria-
Bertani medium containing 100 μg ml−1 of ampicillin, 25 μg ml−1 of kanamycin, and 30 μg 
ml−1 of chloramphenicol until reaching an optical density at 600 nm of 0.6–0.8. After the 
addition of 1 mM IPTG, the cells were further incubated at 16°C for overnight. The 
harvested cells were applied to the protein purification procedure described above. The 
proteins were collected using 100 μl volume of glutathione-immobilized resin. The resin 
bound to the protein was resuspended with lysis buffer to adjust the total volume to 200 μl. 5 
μl of the resuspension separated by SDS-PAGE, which was stained with Coomassie brilliant 
blue, and quantified for protein band density. For each variant, the assay was repeated in 
three independent cell culture.
Degradation assay using human cells
Human embryonic kidney (HEK293T) cells in 12-well plates were co-transfected with 
pcDNA3.1-based A3G or sNTD expression vector (0.66 μg) and pcDNA-HVif, pcDNA-
HVif(H43A Y44A), or empty pcDNA3.1 vector (1.32 μg) by using FuGENE HD 
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(Promega). After the incubation for 24 hours, 2 μM MG132 or dimethylsulfoxide was added 
to the media and the cells were further incubated for 24 hours. Resulting cell lysates were 
separated by SDS-PAGE and immunoprobed by using mouse monoclonal anti-c-myc 
antibody (9E10) (Sigma-Aldrich). The protein bands were visualized and scanned with an 
Odyssey imaging system (LI-COR).
HIV single-cycle assays
Single-cycle infectivity experiments were conducted in triplicate as described35,74. 293T 
cells were maintained in Dulbecco’s modified Eagle medium supplemented with 10% fetal 
bovine serum and 0.5% pen/strep. Cells were plated 250,000 cells per well of a 6-well plate 
and 24 hrs later transfected (TransIT-LT1; Mirus Bio) with 1μg of previously reported Vif-
proficient or Vif-deficient HIV-1 IIIB proviral expression constructs75 and 0ng, 25ng, 50ng, 
or 100ng of A3G-myc expression constructs. DNA quantities were equalized with empty 
pcDNA3.1 (Life Technologies). 48hrs post-transfection, the producer cells and the virus 
containing-supernatants were harvested. A portion of the virus containing-supernatants was 
used to determine infectivity by incubating with CEM-GFP reporter cells plated at 25,000 
cells per well in a 96 well plate following an additional 48 hrs by GFP flow cytometry. The 
remainder of the virus containing-supernatants was centrifuged through a 20% sucrose 
cushion to partially purify viral particles for analysis by immunoblotting. Cell and viral 
pellets were lysed in 2.5X Laemmeli reducing sample buffer for immunoblotting. 
Expression of A3G-myc in cell and viral lysates were detected by use of an anti-c-Myc 
antibody (Sigma-Aldrich) and expression of Vif in cell lysates was detected by an anti-Vif 
antibody (NIH AIDS Reagent Program). Tubulin and p24 served as loading controls for cell 
and viral lysates, respectively, and detected with an anti-tubulin antibody (Covance) and an 
anti-p24 antibody (in-house).
Surface charge and pocket volume analysis
The sNTD NMR structure (Model 1) was used as the template to generate the A3G-NTD 
homology model, using PRIME (Schrödinger, LLC), including energy minimization to 
resolve atomic clashes. Surface electrostatics were calculated in Maestro (Schrödinger, 
LLC). Pocket volume calculations were performed using SiteMap (Schrödinger, LLC).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Generation of soluble N-terminal Vif-binding domain of A3G. (a) Amino acid sequence 
similarities of APOBEC3 proteins. Amino acid sequences of APOBEC3 proteins are aligned 
by ClustalW60, and the branch length represents similarity of amino acid sequences. A3 
proteins are grouped, as described previously39. A3C, A3F CTD and A3G NTD bind HIV-1 
Vif, and all of them belong to the Z2 group. (b) Elution pattern of sNTD by size-exclusion 
chromatography. Elution peaks of Aldolase (158 kDa), Ovalbumine (44kDa) and RNase 
(14kDa) are shown as markers of retention times. (c) sNTD was purified to a single band in 
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an SDS-PAGE gel. Supplementary Data Set 1 provides uncropped form of the SDS-PAGE 
gel.
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Figure 2. 
Solution structure of the Vif-binding domain of A3G. (a) Stereoview of the ten lower-energy 
calculated sNTD structures superimposed using the backbone atoms (N, Cα, and C) of all 
residues except those absent in TROSY spectra, including 19–24, 48–49, 55–56, 67–69, 81–
86, 112–118. These residues are not shown in this figure. (b) Stereoview of a cartoon 
representation of the energy-minimized average structure from ten lowest energy calculated 
sNTD structures. A zinc ion (purple), side chain atoms of zinc coordinating residues, 
including H65, C97, and C100, and of a conserved glutamic acid, E67, are shown with ball-
and-stick representation. (c) Schematic of sNTD secondary structure with helices and 
strands colored orange and blue, respectively.
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Figure 3. 
Structure comparison of sNTD with other APOBEC3 proteins. (a) Cartoon representations 
of structures of the energy-minimized average sNTD (this study), A3A (PDB code, 
2M65)37, A3C (3VOW)38, A3F CTD (4IOU)35 and A3G CTD (3IR2)34 with zinc displayed 
in purple. (b) Enlarged view of the APOBEC3 zinc-binding sites from (a). The side-chains 
of zinc coordinating residues are rendered with ball-and-stick representation. For each 
structure, the top faces to the protein interior, and bottom is accessible to solvent. Zinc is 
shown in gray sphere. (c) Comparison of the α2 and α3 helices. α2 and α3 of sNTD (green) 
are superimposed to that of another APOBEC3 protein, including A3A (2M65)37, A3C 
(3VOW)38, A3F CTD (4IOU)35 and A3G CTD (3IR2)34. Zinc is displayed in green (sNTD) 
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or gray (other A3s). (d) The β1-bulge-β2 region of sNTD is compared with other APOBEC3 
proteins. Each image shows sNTD (green) superimposed on another A3 domain protein 
(gray).
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Figure 4. 
Functional assays of sNTD. (a) E. coli co-expression and GST-pull down assay of sNTD 
and the Vif, CBFβ, elongin B, elongin C complex (VCBC complex). Samples are GST-
fused A3G CTD (lanes 6 and 7), GST-fused sNTD(F126) (lanes 8 and 9) or GST-fused 
sNTD (lanes 10 and 11) expressed together with untagged CBF-β, elonginBC and wild type 
HIV-1 Vif or Vif(H43A Y44A). Lanes 1–5 show reference bands for the expressed protein. 
(b) Locations of D128 and A126 (displayed in green) in the sNTD structure. (c) Vif-
mediated degradation assay using wildtype A3G (A3G) (lanes 1–6), A3G with D128K 
substitution [A3G(D128K)] (lanes 7–12), sNTD fused with wild type CTD (sNTD-CTD) 
(lanes 13–18), sNTD with A126F substitution fused with wild type CTD [sNTD(F126)-
CTD] (lanes 19–24) and sNTD with A126F and D128K double-substitutions fused with 
wild type CTD [sNTD(F126 D128K)-CTD] (lanes 25–30). Alpha-isoform of tubulin (α-
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tubulin) was used as a loading control. Vif (wt) is wildtype Vif, and Vif (H43A Y44A) 
contains alanine substitutions of H43 and Y44. (d) Single cycle infectivity experiment 
comparing wildtype A3G and full-length variants with sNTD(F126)-CTD and sNTD-CTD. 
The histogram reports the infectivity of Vif-deficient (Vifxx) or Vif-proficient (WT) HIV-1 
IIIB produced in 293T cells expressing the indicated A3G-myc construct (0, 25, 50, 100 ng) 
(graph shows mean values ± s. d. n = 3 independent cell cultures). The corresponding 
immunoblots show expression levels of relevant proteins in cell lysates (anti-myc for A3G-
myc, anti-Vif, and anti-Tubulin) and virus-like particles (VLPs; anti-myc for A3G-myc and 
anti-p24). alpha-isoform of tubulin (α-tubulin) was used as a loading control.
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Figure 5. 
Identification of Vif-binding regions of sNTD. (a) Relative Vif-binding capabilities of sNTD 
variants tested using E. coli co-expression and GST-pull down assay. The ratio between 
protein amounts of [GST-sNTD variant] and [Vif, CBF-β, elonginBC] is plotted (graph 
shows average values ± s. d. n = 3 independent cell cultures). Representative images of 
SDS-PAGE gels are provided in supplemental figure 5g (experiments were repeated three 
times using independent cell cultures). (b) Residues whose substitution reduced sNTD 
binding to the VCBC complex by greater than 50% are shown in red on the sNTD structure. 
The position of F126 is shown in green. (c) Residues whose substitution resulted in greater 
than 50% reduction of A3G Vif-binding as reported49 are shown in red. (d) and (e) highlight 
A3C and A3F CTD residues that upon substitution cause greater than 50% reduction in Vif-
binding, respectively38.
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Table 1
NMR and refinement statistics for protein structures
Protein
NMR distance and dihedral constraints
Distance constraints
 Total NOE 1543
 Intra-residue 676
 Inter-residue
  Sequential (|i – j| = 1) 338
  Medium-range (|i – j| < 4) 183
  Long-range (|i – j| > 5) 346
  Intermolecular 0
 Hydrogen bonds 33 (66)
Total dihedral angle restraints
 ϕ 106
 ψ 0
Structure statistics
Violations (mean ± s.d.)
 Distance constraints (Å) 0.07 ± 0.06
 Dihedral angle constraints (°) 0.90 ± 0.77
 Max. dihedral angle violation (°) 3.70
 Max. distance constraint violation (Å) 0.30
Deviations from idealized geometry
 Bond lengths (Å) 0.004546 ± 0.000087
 Bond angles (°) 0.6737 ± 0.0076
 Impropers (°) 0.4877 ± 0.0153
Average pairwise r.m.s. deviation** (Å)
 Heavy 1.57 ± 0.17
 Backbone 0.82 ± 0.17
**
Pairwise r.m.s. deviation was calculated among ## refined structures.
Total RDCs
Qfree (%)
Q and Qfree is recommended in the case where there are many RDCs, often though there are not enough to make this statistically meaningful
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